What it is
- A tripeptide (lysine-proline-valine) corresponding to the C-terminal end of alpha-melanocyte-stimulating hormone.
What researchers have investigated
- Explored in laboratory and animal models of inflammation, including intestinal inflammation.
Type of evidence
- Preclinical.
What remains unknown
- Any human benefit, safe dosing, and long-term effects.
Safety & regulatory context
- Not FDA approved for human use. Verify status individually.
Inclusion does not imply availability.
Level Health does not sell, prescribe or recommend KPV. Findings in animals or cells do not establish benefits in people.
Primary sources: PubMed search for KPV. Reviewed by: pending. Last reviewed: pending.